PDL BioPharma (PDLI) Gains on Buying into AcelRx

September 21, 2015 11:12 AM | 14 seconds read |
PDL BioPharma Inc PDLI shares gained 0.8% to $5.32, after the company announced the acquisition of portion of AcelRx Pharma's expected royalties and milestones from Zalviso for $65 million. Share volume was 243,000, compared to an all-day average of 2.5 million
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!